King Keytruda flounders in another pivotal cancer study. And that may spur doubts about Merck's staying power
The king of the PD-(L)1 class is seeing a few cracks start to appear in the crown.
Merck reported Tuesday evening that its Phase III pivotal dubbed KEYNOTE-361 failed to show a significant advantage for Keytruda/chemo combo patients over chemo alone in frontline bladder cancer. And coming after some mixed results for triple negative breast cancer and not so hot results for small cell lung cancers, the latest setback is likely to leave some analysts wondering how Merck’s many rivals are likely to take advantage of the weakness.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.